<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1509">
  <stage>Registered</stage>
  <submitdate>23/03/2007</submitdate>
  <approvaldate>23/03/2007</approvaldate>
  <nctid>NCT00451971</nctid>
  <trial_identification>
    <studytitle>Objective Study in Rheumatoid Arthritis</studytitle>
    <scientifictitle>Objective Study in Rheumatoid Arthritis</scientifictitle>
    <utrn />
    <trialacronym>OSRA</trialacronym>
    <secondaryid>HWA486_4020</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Arthritis, Rheumatoid</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - LEFLUNOMIDE

Treatment: drugs: LEFLUNOMIDE


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Long Term Objective (damage) is the MRI which will be undertaken at baseline, 12 months and 24 months.</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The Short Term Objectives are: swollen joint count - target:(28) = 2 joints</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>C-Reactive Protein - target: within the normal range (provided elevation is not due clinically to an intercurrent event)</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: Full blood count and erythrocyte sedimentation, blood urea, electrolytes, creatinine and Liver function test</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Rheumatoid Arthritis as defined by the American College of Rhemuatology criteria and
             either

          -  Active disease: =6/28 swollen joints or

          -  Erythrocyte sedimantation or C-Reactive Protein &gt; normal

          -  Disease duration = 15 yrs

          -  Any therapy

          -  Females of child-bearing potential must be adequate contraception</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Frailty, limiting co-morbidity

          -  Obesity limiting ability to have MRI

          -  Geographical difficulty preventing follow-up and visits

          -  Women at risk of becoming pregnant

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>249</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Sanofi-Aventis - Sydney</hospital>
    <postcode> - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Primary Objectives

        1. To test the feasibility, in patients with active rheumatoid arthritis, of using an
           'aggressive' treatment algorithm to bring a short term treatment objective (STO) within
           the normal or an arbitrarily defined 'desirable' range.

        2. To determine whether patients with active rheumatoid arthritis randomly allocated to a
           particular STO show a reduced rate of Magnetic resonance imaging damage progression at
           two years compared to those randomly allocated to usual care.

      Secondary Objectives

        1. To establish the relationship between achieving a given STO or combination of STOs and
           damage progression.

        2. To identify the characteristics of responders and non-responders with respect to STO
           achievement and predictors of greater and lesser degrees of damage progression.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00451971</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>J Edmonds</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>